Last reviewed · How we verify
Debio 4126
Debio 4126 is a selective inhibitor of mitochondrial complex I that disrupts energy metabolism in cancer cells.
Debio 4126 is a selective inhibitor of mitochondrial complex I that disrupts energy metabolism in cancer cells. Used for Advanced solid tumors (Phase 3 development).
At a glance
| Generic name | Debio 4126 |
|---|---|
| Sponsor | Debiopharm International SA |
| Drug class | Mitochondrial complex I inhibitor |
| Target | Mitochondrial complex I (NADH dehydrogenase) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The drug targets mitochondrial NADH dehydrogenase (complex I), impairing ATP production and inducing metabolic stress in tumor cells. This mechanism is particularly relevant in cancers with high metabolic demands or specific mitochondrial dependencies. The selective targeting aims to exploit metabolic vulnerabilities in cancer while minimizing effects on normal tissues.
Approved indications
- Advanced solid tumors (Phase 3 development)
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Anemia
Key clinical trials
- A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs (PHASE3)
- A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Debio 4126 CI brief — competitive landscape report
- Debio 4126 updates RSS · CI watch RSS
- Debiopharm International SA portfolio CI